Navigation Links
PhaseRx Appoints Michael Houston, Ph.D., Vice President, Therapeutics Development
Date:1/10/2014

SEATTLE, Jan. 10, 2014 /PRNewswire/ -- PhaseRx, Inc., an RNA therapeutics company, today announced the appointment of Michael Houston, Ph.D., as its Vice President, Therapeutics Development.

(Logo: http://photos.prnewswire.com/prnh/20140110/SF44129LOGO)

Dr. Houston brings more than two decades of experience in the manufacturing and development of peptide and oligonucleotide-based therapeutics to PhaseRx.  He has directed numerous programs ranging from research to GMP manufacture of clinical trials materials, including nanoparticle-based delivery vehicles for siRNAs. In this new position, Dr. Houston will lead PhaseRx's therapeutics program, which focuses on the advancement of its SMARTT Polymer Technology® mRNA nanoparticles.

"Mike is a great addition to the PhaseRx team as we focus on the advancement of our SMARTT Polymer Technology RNA programs into clinical development," said Robert Overell, Ph.D., President and Chief Executive Officer at PhaseRx. "Mike's experience in the synthesis, manufacture and production of RNA therapeutics including nanoparticle-based formulations, will accelerate our efforts to apply SMARTT technology to address the significant unmet treatment need in orphan liver diseases."

Dr. Houston joins PhaseRx from Marina Biotech where he served as Vice President, Chemistry and Formulations and focused on the development of siRNAS and single stranded oligonucleotides. He has also served at Ascent Therapeutics as Vice President, Preclinical Chemistry and CMC; at MDRNA, Inc. as Vice President, Chemistry & Formulations; and at Nastech Pharmaceuticals as Senior Director, Chemistry and Formulations. Dr. Houston received a Ph.D. in bio-organic chemistry and a B.Sc. with honours in chemistry from the University of Waterloo, Ontario, Canada.

PhaseRx's SMARTT Polymer Technology (SMARTT) mediates endosome escape and mRNA delivery into cytoplasm, overcoming the key stumbling block to the delivery of mRNA drugs into cells.  SMARTT has been developed into an industrialized system that is well-tolerated in small and large animal models, does not induce innate immunity and provides robust, scalable manufacture. PhaseRx is evaluating several disease targets for SMARTT and will be selecting its lead program in 2014.

About PhaseRx
PhaseRx is privately held RNA therapeutics company developing treatments for orphan liver disease. The Company is utilizing its proprietary SMARTT Polymer Technology®, which offers the ability to deliver messenger RNA therapeutics predictably to selected tissues in vivo, thereby unlocking the value of mRNA as a new therapeutic modality. PhaseRx is headquartered in Seattle, Wash. For more information, visit www.phaserx.com.  

Contact: 
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com                                  
206.769.9219

 


'/>"/>
SOURCE PhaseRx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Chief Financial Officer Jonathan M. Peacock to Leave Amgen; Company Appoints Michael A. Kelly Acting Chief Financial Officer
2. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
3. Mylan Appoints Adele Gulfo as EVP, Global Collaboration and Strategic Operations
4. Lakewood-Amedex Inc. Appoints Geoffrey F. Cox To Its Board Of Directors
5. Kite Pharma Appoints Cynthia M. Butitta as Chief Financial Officer
6. Auspex Raises $35 Million And Appoints Industry Veteran Gerald Proehl To Its Board of Directors
7. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
8. KaloBios Appoints Harry Lam, Ph.D. as Head of Manufacturing
9. MIMETAS Appoints BHI Entrepreneur-in-Residence Todd Chappell as General Manager, U.S. Affairs
10. Ajinomoto Althea Inc. Appoints J. David Enloe Jr. as President and Chief Executive Officer
11. Concord Medical Announces Results of 2013 Annual General Meeting; Appoints New Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... DUBLIN , Feb. 24, 2017 Research ... Health Market Analysis & Trends - Industry Forecast to 2025" ... ... at a CAGR of around 23.8% over the next decade to ... analyzes the market estimates and forecasts for all the given segments ...
(Date:2/24/2017)... Research and Markets has announced the addition of ... to 2025" report to their offering. ... The Global Empty Capsules Market is poised to grow ... approximately $2.9 billion by 2025. This industry report analyzes ... as well as regional levels presented in the research scope. The study ...
(Date:2/24/2017)... Research and Markets has announced the addition of the "Dry ... offering. ... Dry eye Drugs Price Analysis and Strategies - 2016, provides drug pricing ... answers the following questions: What are the ... they positioned in the Global Dry eye market? What ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... , ... IndustryArchive.Org . is announcing a new way for B2B Sellers ... only pay for B.A.N.T. quality sales leads based on the Sellers decision to purchase ... reality that B2B buyers are controlling the sales process via the Internet and that ...
(Date:2/26/2017)... ... ... ODH, Inc.™ announced today it will exhibit and speak at the 10th ... Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present on how ... management. , ODH will also have an exhibit booth where attendees may speak to ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide ... with a specific LRRK2 mutation, according to a study released today at the ... evidence of a link between pesticides and incidence of sporadic PD through occupational ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, ... Go. Core benefits and advantages built into the home office sit stand solution ... and feel. Ability to gain the benefits embedded in the TaskMate Go are ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release ... show in Cannes (France), XO Private has initiated a second print-run of its lavish ... almost a metre across when open, weighs in at more than six kilos, retails ...
Breaking Medicine News(10 mins):